论文信息 - Maximising returns: combining newborn screening with gene therapy for spinal muscular atrophy - 字舞流文

Maximising returns: combining newborn screening with gene therapy for spinal muscular atrophy

T. Gillingwater

[1] M. Farrar,et al. Newborn screening for spinal muscular atrophy with disease-modifying therapies: a cost-effectiveness analysis , 2021, Journal of Neurology, Neurosurgery, and Psychiatry.

[2] T. Gillingwater,et al. Spinal muscular atrophy: From approved therapies to future therapeutic targets for personalized medicine , 2021, Cell reports. Medicine.

[3] Jonathan J. Darrow,et al. Efficacy and costs of spinal muscular atrophy drugs , 2020, Science Translational Medicine.

[4] Ewout J. N. Groen,et al. Advances in therapy for spinal muscular atrophy: promises and challenges , 2018, Nature Reviews Neurology.

[5] A. T. van der Ploeg,et al. The Dilemma of Two Innovative Therapies for Spinal Muscular Atrophy. , 2017, The New England journal of medicine.